TBG Diagnostics Ltd, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits and instruments in the United States, Taiwan, and China. Its reagents include COVID 19 testing, HLA SSP and HLA SBT typing, HPA genotyping, and Nucleic Acid Extraction kits; reagents and accessories; Holotype HLA NGS; and reagent analysis software. The company offers equipment, such as nucleic acid extraction, automated pipetting, and real time PCR systems. In addition, it provides HLA-typing services, as well as engages in research and development. The company serves clinical labs, blood centers, and bone marrow registry labs. TBG Diagnostics Ltd was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Ltd in December 2015. The company was incorporated in 1989 is based in Melbourne, Australia. TBG Diagnostics Ltd operates as a subsidiary of Medigen Biotechnology Corp.